Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR

EGFR is a protein kinase whose aberrant activity is frequently involved in the development of non-small lung cancer (NSCLC) drug resistant forms. The allosteric inhibition of this enzyme is currently one among the most attractive approaches to design and develop anticancer drugs. In a previous study...

Full description

Bibliographic Details

Published in:	Journal of Enzyme Inhibition and Medicinal Chemistry
Main Authors:	Francesca Foschi, Annachiara Tinivella, Valentina Crippa, Luca Pinzi, Luca Mologni, Daniele Passarella, Giulio Rastelli
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	EGFR inhibitors allosteric inhibitors anticancer drugs drug design
Online Access:	https://www.tandfonline.com/doi/10.1080/14756366.2022.2145284